Upadacitinib vs. Infliximab for Severe Ulcerative Colitis
Treatments studied
Part of Digestive system, Immune system & allergy clinical trials.
This study compares two medications—upadacitinib and infliximab—as second-line treatments for acute severe ulcerative colitis (a serious flare of inflammatory bowel disease). The trial will help doctors understand which treatment works better when standard first-line therapy hasn't controlled the inflammation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Diagnosed with acute severe ulcerative colitis (ASUC)—a serious, sudden flare of your ulcerative colitis
- Age 18 or older
- No allergy or previous severe reaction to upadacitinib or infliximab
- No current or recent cancer diagnosis
- No serious heart, lung, liver, or kidney disease
- Not pregnant or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares a newer medication called upadacitinib to traditional steroids for treating acute severe ulcerative colitis (sudden worsening of UC with bloody diarrhea and urgent symptoms). The goal is to see which approach works better as a first treatment.
This trial tests if combining two medications, infliximab and tofacitinib, works better than standard treatment for adults hospitalized with a severe flare of ulcerative colitis. If you have not been on these drugs before and meet certain health criteria, you may be able to join.
This trial tests two different medicines, infliximab and upadacitinib, to see which works better for people with severe ulcerative colitis that hasn't improved after 3 days of IV steroids. The goal is to find the best rescue option to help you feel better and avoid surgery.
This trial tests a medication called upadacitinib for people hospitalized with a severe ulcerative colitis flare. It could help control inflammation and reduce symptoms.
This trial tests if a higher dose of upadacitinib can help people with ulcerative colitis who stopped responding to the 30 mg daily dose. It aims to see if re-inducing with a stronger dose can bring back symptom control.
This study tests a medication called upadacitinib for people with inflammatory bowel disease (ulcerative colitis or Crohn's). The goal is to see how well it works and if it's safe.
Hear when a new Acute Severe Ulcerative Colitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.